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Abstract
Background: Due to prophylactic colectomy, mortality in patients with familial adenomatous polyposis (FAP) has
changed, with duodenal cancer currently being the main cause of death. Although celecoxib reduces duodenal
polyp density in patients with FAP, its long-term use may increase the risk of cardiovascular events and alternatives
need to be explored. Preclinical studies suggest that the combination of celecoxib with ursodeoxycholic acid
(UDCA) is a potentially effective strategy. We performed a randomized, double-blind, placebo-controlled trial to
investigate the effect of celecoxib and UDCA co-treatment on duodenal adenomatosis in patients with FAP.
Methods: Patients with FAP received celecoxib (400 mg twice daily) and UDCA (1000-2000 mg daily, ~20-30 mg/kg/day,
n=19) or celecoxib and placebo (n=18) orally for 6 months. Primary outcome was drug efficacy, assessed by
comparing duodenal polyp density at pre- and post-intervention by blinded review of endoscopic recordings. As
secondary outcomes, cell proliferation, apoptosis, and COX-2 levels in normal duodenal mucosa were assessed by
immunohistochemistry or real-time quantitative polymerase chain reaction.
Results: In intention-to-treat analysis, deceased polyp density was observed after celecoxib/placebo treatment
(p=0.029), whereas increased polyp density was observed after celecoxib/UDCA treatment (p=0.014). The
difference in change in duodenal polyp density was statistically significant between the groups (p=0.011). No
changes in secondary outcomes were observed. Thirty patients (81%) reported one or more adverse events, 16
patients (84%, Common Toxicity Criteria for Adverse Events version 3.0 (CTCAE) grade 1–3) treated with celecoxib/
UDCA and 14 patients (78%, CTCAE grade 1–2) treated with celecoxib/placebo. Nine patients (24%) discontinued
intervention prematurely, 5 patients (26%) treated with celecoxib/UDCA and 4 patients (22%) treated with
celecoxib/placebo.
Conclusions: Celecoxib reduces duodenal polyp density in patients with FAP, and unexpectedly, high dose UDCA
co-treatment counteracts this effect. The benefit of long term use of celecoxib for duodenal cancer prevention
needs to be weighed against the (risk of) adverse events.
Trial registration: http://ClinicalTrials.gov, identifier NCT00808743
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Background
In the past decades, prophylactic colectomy to prevent
development of colorectal cancer substantially improved
prognosis in patients with familial adenomatous polyp-
osis (FAP; OMIM #175100) [1]. The mortality pattern
has changed and duodenal cancer now is the main
cancer-related cause of death [2,3]. Lifetime risk of duo-
denal adenomas approaches 100% [4], and approxi-
mately 3-7% of patients develop duodenal cancer [5,6].
As duodenal cancer in patients with FAP has a poor
prognosis [7,8], the clinical challenge is to identify pa-
tients with high-risk duodenal adenomas and intervene
before progression to cancer occurs. Prophylactic duode-
nectomy may offer a prolonged disease-free interval, but
is associated with substantial morbidity and mortality
[9,10]. Therefore, chemoprevention would be highly de-
sirable to postpone or even avoid the necessity for rad-
ical surgery.
Cyclooxygenase (COX) inhibiting non-steroidal anti-
inflammatory drugs (NSAIDs) have been investigated ex-
tensively as potential chemopreventive drugs. COX-2 is
induced in inflammatory and tumorigenic settings [11].
Overexpression of COX-2, as found in colorectal aden-
omas and carcinomas, was linked to reduced apoptosis,
enhanced cell growth, tumour angiogenesis, tissue invasion,
and metastasis [11]. Treatment with the COX-2 inhibitor
celecoxib resulted in regression of colorectal adenomas in
patients with FAP [12], as well as in significant decrease in
sporadic colorectal adenomas [13,14].
For duodenal polyposis, the value of COX inhibiting
agents is not yet established [15]. Sulindac showed re-
gression of small duodenal polyps in patients with FAP
[16,17], but had no benefit in controlling periampullary
polyposis [18]. The significant reduction in duodenal
polyp density after 6 months of treatment with
high dose celecoxib in patients with FAP with clinically
significant disease was promising [19].
Unfortunately, suitability of COX-2 inhibitors for
long-term use is subject of discussion, due to increased
risks of adverse cardiovascular events [13,14,20]. Com-
bining celecoxib with other potentially effective drugs
could be a more effective strategy. A candidate drug is
ursodeoxycholic acid (UDCA), for a number of reasons.
First, the clustering of adenomas around the ampulla of
Vater suggests that bile plays a role in duodenal ade-
nomatosis [21]. In in vitro models of human colorectal
cancer cells, UDCA significantly reduced cytotoxicity of
secondary bile acids [22], and celecoxib and UDCA co-
treatment inhibited cell growth in colorectal adenoma
cells from a patient with FAP [23]. Second, clinical stud-
ies showed chemopreventive effects of UDCA on de-
velopment of colorectal neoplasms, in patients with
sporadic colorectal adenomas, and in patients with ul-
cerative colitis (UC) and primary sclerosing cholangitis
(PSC) [24-26]. Third, UDCA was found to suppress
COX-2 levels in a rat model of colonic carcinogenesis
[27], suggesting an alternative pathway for COX-2 inhib-
ition [28]. Finally, in a mouse model of FAP, sulindac
and UDCA co-treatment showed synergistic effects in
the prevention of intestinal adenomas [29].
Based on these findings, the aim of the present ran-
domized controlled trial was to examine the effect of
celecoxib plus UDCA co-treatment, in comparison to
celecoxib plus placebo, on duodenal adenomatosis in pa-
tients with FAP. We hypothesized that adding UDCA to
the treatment with celecoxib results in a further reduc-
tion of duodenal polyp density.
Patients and methods
This clinical trial (http://ClinicalTrials.gov number NCT
00808743) was conducted according to ICH Good Clinical
Practice and complied with the principles of the amended
Declaration of Helsinki and Dutch legislation. Ethical
approval was obtained at the initiating centre Radboud
University Nijmegen Medical Centre (RUNMC; Proto-
col approval number 2008/148; CCMO number NL235
69.091.08). In the other participating centres, feasibility
was approved by the local Medical Ethics Committees.
All study participants provided written informed con-
sent. The study was monitored by a RUNMC Safety
Monitoring Board.
Study participants
The study population consisted of patients with FAP
recruited from the cohort under regular surveillance at the
RUNMC, Academic Medical Centre Amsterdam (AMC),
Erasmus Medical Centre Rotterdam (EMC), University
Medical Centre Groningen (UMCG), and Leiden University
Medical Centre (LUMC). The study was conducted be-
tween June 2009 and June 2011.
The diagnosis FAP was established either clinically, by
the presence of >100 colorectal polyps, or genetically, by
the presence of adenomatous polyposis coli (APC) gene
mutations. Eligible patients were between 18 and 70 years
of age, capable of informed consent, had Spigelman stage
II or III duodenal adenomatosis at last surveillance duo-
denoscopy, and had no history of surgical duodenal re-
section. Exclusion criteria included peptic ulcer disease,
inflammatory bowel disease, cardiovascular disease (con-
gestive cardiac failure with New York Heart Association
class ≥II; history of ischemic heart disease and/or cerebro-
vascular disease) or significant cardiovascular risk (at least
two of the following risk factors: hypertension, hyperchol-
esterolaemia, diabetes mellitus, ≥2 first degree relatives
with cardiovascular event below the age of 55 years), ab-
normal results on a full blood count or abnormal liver or
renal function tests, known intolerability of NSAIDs,
sulfonamids, or UDCA, use of NSAIDs or UDCA for >1
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week during 6 months prior to study entry, use of lithium,
and pregnancy or lactation.
Study procedures
Evaluation at baseline included history taking, physical
examination, and clinical laboratory evaluation (full blood
count, liver and renal function, cholesterol). Endoscopic
procedures were performed using a side-viewing endo-
scope (Olympus TJF-160, Olympus Medical Systems Europe,
Hamburg, Germany) and a forward-viewing endoscope
(Olympus GIF-1T-Q160) successively. Endoscopic pro-
cedures were recorded digitally. After completion of the
recording procedures, six random biopsies of normal ap-
pearing mucosa were taken in the second (D2) portion of
the duodenum. Two biopsies were fixed in formalin and
embedded in paraffin, four biopsies were snap frozen in li-
quid nitrogen and stored at −80°C. Biopsies were taken
using an Olympus Endojaw FB-232U with open forceps
diameter 9mm, or a Boston Scientific Radial Jaw 3 with
open forceps diameter 8mm (Boston Scientific, Natick,
MA, USA). Procedures were repeated after 6 months. At
baseline, no biopsies of adenomatous lesions were taken,
as this could influence primary outcome.
After completion of pre-intervention duodenoscopy, pa-
tients were randomly assigned to one of two treatment
groups in an 1:1 ratio. Randomization was performed at
the Department of Clinical Pharmacy RUNMC, by a
computer-generated schedule, to assign sequentially num-
bered treatment packs in randomized blocks of four. Pa-
tients, physicians, and investigators were blinded to
treatment allocation. Patients in group A received orally
for 6 months: celecoxib (Celebrex, Pfizer, New York, NY,
USA) 400 mg twice daily (once daily during the first 2
weeks), in combination with UDCA (Ursofalk, Dr Falk
Pharma, Freiburg, Germany). Patients in study group B re-
ceived orally for 6 months: celecoxib 400mg twice daily
(once daily during the first 2 weeks), in combination with
an UDCA identical-appearing placebo (Dr Falk Pharma).
UDCA/placebo was given in two daily doses, with total
daily UDCA dose based on body weight: ≤50 kg: 1000 mg,
50-70 kg: 1500 mg, >70 kg: 2000 mg (~20-30 mg/kg/day).
UDCA starting dose was 500 mg, which was raised with
500 mg every 2 weeks until maximum dose was reached.
The placebo contained lactose and cellulose.
Information on adverse events (AEs) was obtained
during patient contacts by telephone at 1 and 3 months,
and prior to post-intervention duodenoscopy at 6 months.
Monitoring of blood pressure and clinical laboratory pa-
rameters was performed at 1 and 6 months. AEs were
graded as defined by the Common Toxicity Criteria for
Adverse Events version 3.0 (CTCAE v3.0) [30]. Compli-
ance was monitored by means of pill counts and review of
diaries completed by the patients.
Disclosure of randomization was performed by the
Department of Clinical Pharmacy RUNMC on December
10th 2012, after completion of assessment of recorded
duodenoscopies and all tissue analyses.
Assessment of recorded endoscopic procedures
Endoscopic recordings were analyzed using qualitative
assessment of duodenal polyp density, as previously de-
scribed in patients with FAP for the colorectum [12] and
duodenum [19]. In short, five gastroenterologists expe-
rienced in management of FAP (ED, JD, JJK, AMJL,
FMN), independently scored the blinded pairs of pre-
and post-intervention videos of each patient, shown in
random order. Pairs were scored as no change (scored
as 0), clinical improvement (scored as +1), or clinical de-
terioration (scored as −1) in polyp density. Based on the
scores of the five gastroenterologists, mean scores of
change in duodenal polyp density were calculated for
each patient. Patients that discontinued intervention
prematurely were included in intention-to-treat analysis
with a score of change in duodenal polyp density of −0.5.
Immunohistochemical staining for cell proliferation,
apoptosis, and COX-2
Tissue sections of 4 μm were cut from paraffin blocks,
mounted on electrostatic slides (Super Frost Plus,
Menzel-Gläser, Baunschweig, Germany) and stained with
Hematoxylin & Eosin (H&E). Only samples with normal
histology (non-dysplastic and non-adenomatous mucosa),
as verified by an expert pathologist (IDN), were used for
further analyses.
Tissue sections were deparaffinized and dehydrated. En-
dogenous peroxidase was blocked with 3% hydrogen per-
oxide. Subsequently, heat-induced antigen retrieval was
performed in sodium citrate buffer (10 mmol/L, pH=6).
Cell proliferation activity was assessed after staining for 1
hour at room temperature with mouse anti-human MIB-1
monoclonal antibody (Dako A/S, Glostrup, Denmark)
at dilution 1:200. MIB-1 recognizes the Ki-67 nuclear anti-
gen of dividing cells [31]. Apoptosis was assessed by
staining overnight at 4°C with mouse anti-human M30
CytoDEATH monoclonal antibody (Roche Diagnostics,
Mannheim, Germany) at dilution 1:400. M30 recognizes
cleaved cytokeratin 18, expressed in epithelial cells during
early apoptosis [32]. COX-2 was assessed by staining over-
night at 4°C with mouse anti-human COX-2 monoclonal
antibody (Cayman Chemical, Ann Arbor, MI, USA) at di-
lution 1:100. Visualization of MIB-1 was achieved using
the Brightvision (1:1)/BrightDab detection system (Im-
munologic, Duiven, The Netherlands), whereas M30 and
COX-2 were visualized using the avidin-biotin peroxidase
complex method (Vector Laboratories, Burlingame, CA,
USA). Mayer hematoxylin counterstaining was applied.
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Tissue sections of colorectal carcinomas were used as
positive controls.
Evaluation of immunohistochemical staining and scoring
Tissue samples were independently evaluated by light mi-
croscopy (Leica Microsystems, Rijswijk, The Netherlands)
by two investigators (BWHvH, MEV-B). If scores differed,
a consensus agreement was reached during re-evaluation.
A random selection of 10% of scores were re-evaluated
and verified by an expert pathologist (IDN). Cell prolifera-
tion index was expressed as percentage of MIB-1 positive
epithelial cells in areas of the tissue section with well-
orientated crypt-villi architecture. Apoptotic index was ex-
pressed as number of M30 positive epithelial cells per mm2
tissue area. COX-2 staining in epithelial cells was scored
as previously described [33]: 0, no staining; 1, weak cy-
toplasmatic and membranous staining (may contain
strong staining in <10% of cells); 2, moderate-to-strong
staining in 10-90% of cells; and 3, strong staining in >90%
of cells.
RNA isolation and real-time quantitative polymerase
chain reaction (qPCR) for COX-2
One biopsy sample of each location was weighed and
taken up in 200 μl TRIzol (Life Technologies, Pailey,
UK). Tissue was homogenized by 10 strokes with a Tef-
lon pestle. After homogenization, another 600 μl TRIzol
was added. Total RNA was extracted according to the
manufacturer’s instructions (Life Technologies) with a
slight modification: prior to precipitating the RNA with
isopropyl alcohol, 7.5 μg RNAse-free glycogen was added
to the aqueous phase. Approximately 1 μg RNA was
converted into cDNA according to the instructions
provided by the Roche Transcriptor High Fidelity cDNA
synthesis kit (Roche Diagnostics). Detection and quantifi-
cation of COX-2 mRNA was performed by qPCR using
the CFX96 Real-Time PCR Detection System (Bio-Rad
Laboratories, Hercules, CA, USA). Analysis of COX-2
expression was performed using two different COX-2
specific primer sets: forward 5’-GGCGCTCAGCCATAC
AG-3’(exon 1) with reverse 5’-CCGGGTACAACTGCA
CTTAT-3’(exon 2) and forward 5’-GGCGCTCAGCCAT
ACAG-3’(exon 1) with reverse 5’-TCTTGTCAAAAATT
CCGGTG-3’ (exons 2 and 3) (Isogen Life Science,
Maarssen, The Netherlands). PCR products were detected
with SYBR Green (Molecular Probes, Eugene, OR, USA).
Specificity of COX-2 PCR products was checked using
melting curve analysis and agarose gel electrophoresis.
Levels of β-2 microglobulin (β2M) mRNA were used as a
normalizing control. Analysis of β2M was performed with
the primers 5’-ATGAGTATGCCTGCCGTGTG- 3’ and 5’-
CCAAATGCGGCATCTTCAAAC-3’ with a specific probe
5’-FAMCGCGTCGTGGGATGGAGACATGTAAGCAGA
CGCGDabcyl- 3’ (Biolegio, Nijmegen, The Netherlands).
The β2M product was checked by agarose gel electro-
phoresis. qPCR procedures were performed in triplicate or
quadruplicate and mean Ct values were calculated.
Statistical analysis
Baseline characteristics were expressed as percentage or
medians with range when appropriate. Continuous vari-
ables were considered to be not normally distributed.
Differences between treatment groups on continuous
variables were tested using Mann–Whitney U test, and
differences on discrete variables were examined using
Chi-square test, or Fisher’s exact test when appropriate.
Differences on continuous and ordinal variables within
treatment groups, comparing pre- and post-intervention
measurements, were examined using Wilcoxon Signed
Rank test and McNemar’s test, respectively. Analyses of
primary outcome were performed on an intention-to-
treat basis, with a per-protocol analysis as sensitivity
analysis. P value of <0.05 (2-sided) was considered statis-
tically significant. Statistical analysis was performed using
SPSS statistical software version 21 (IBM SPSS, Chicago,
IL, USA).
Results
Patient characteristics
The CONSORT diagram of the study is depicted in
Figure 1. Of all patients with FAP that were under regular
surveillance in the five participating University hospitals,
94 patients were eligible for inclusion. Twenty-three pa-
tients were excluded based on exclusion criteria and 29
patients declined informed consent. Forty-two patients
underwent initial duodenoscopy, of which five patients
were not randomized: four had insufficient polyps and
one patient required treatment because of advanced duo-
denal adenomatosis. Thirty-seven patients were random-
ized: 19 patients received celecoxib & UDCA (group A)
and 18 patients received celecoxib & placebo (group B).
Patient characteristics are depicted in Table 1. Due to
technical failure, either pre- or post-intervention record-
ings could not be analysed in five patients. Consequently,
thirty-two patients (group A, n=17; group B, n=15) were
analysed on an intention-to-treat basis for the primary
outcome. Nine patients (24.3%) discontinued intervention
prior to duodenoscopy at six months. Consequently, per-
protocol analysis was performed on 23 patients (group A,
n=12; group B, n=11).
Primary outcome: change in duodenal polyp density
In the intention-to-treat analysis, clinical deterioration
(n=17, median= −0.2, range: -0.6-+0.4) in duodenal polyp
density was observed in group A (Wilcoxon Signed Rank,
p=0.014), receiving celecoxib & UDCA, while clinical im-
provement (n=15, median=0.6, range: -0.5-+1.0) was
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observed in group B (Wilcoxon Signed Rank, p=0.029), re-
ceiving celecoxib & placebo (Figure 2). The difference in
mean score of change in duodenal polyp density was sta-
tistically significant between groups (Mann–Whitney U,
p=0.011).
In the per-protocol analyses, the difference in mean
score of change in duodenal polyp density between group
A (n=12, median=−0.2, range: -0.6-+0.4) and group B
(n=11, median=0.8, range: 0.0-+1.0) was more pronounced
(Mann–Whitney U, p<0.001). Clinical deterioration in
duodenal polyp density observed in group A was not sta-
tistically significant (Wilcoxon Signed Rank, p=0.271), in
contrast to the clinical improvement observed in group B
(p=0.004).
Secundary outcome: cell proliferation, apoptosis, and
COX-2 immunohistochemistry
Changes in cell proliferation, apoptosis, and COX-2 were
evaluated in all patients that completed the intervention
period and underwent pre- and post-intervention duode-
noscopy, with one additional patient excluded in group
B of whom post-intervention biopsies could not be
assessed (n=27).
Median difference in cell proliferation pre- versus
post-intervention was not statistically significant be-
tween both treatment groups (group A: n=14, median
difference =−5.0%, range=−20.0%-10.0%; group B: n=13,
median difference=0.0%, range: -15.0%-20.0%; Mann–
Whitney U, p=0.141). The median decrease in cell prolif-
eration of 5.0% observed in group A was not statistically
significant (Wilcoxon Signed Rank, p=0.057).
No M30 positive apoptotic epithelial cells were scored
in any of the evaluated samples, except for positive con-
trol samples.
COX-2 staining was scored as either moderate-to-strong
or strong staining in all evaluated samples. No difference
in COX-2 staining was seen comparing pre- and post-
intervention: in group A, a decreased score was observed
in 2 patients, an equal score in 8 patients, and an in-
creased score in 3 patients (McNemar, p=1.000). In group
B, a decreased score was observed in 4 patients, an equal
score in 6 patients, and an increased score in 2 patients
(McNemar, p=0.688).
Figure 1 CONSORT diagram. FAP = familial adenomatous polyposis; NSAID = non-steroidal anti-inflammatory drugs; UDCA = ursodeoxycholic acid.
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Secondary outcome: COX-2 mRNA analyses
COX-2 mRNA expression was also evaluated in all
patients that completed the intervention period, with
the noted one additional patient excluded in group B
(n=27).
In 12 patients (group A: n=6, group B: n=6), no
measurable COX-2 mRNA levels were present in ei-
ther pre- or post-intervention sample. In all other
cases, low COX-2 mRNA levels seemed present, but
specificity of PCR products could not be confirmed by
melting curve analyses and agarose gel electrophor-
esis. Experiments in which the second set of specific
COX-2 primers were used, showed the same results.
Simultaneous qPCR analyses on colorectal cancer tis-
sue samples showed high levels of COX-2 specific
qPCR products.
Adverse events and compliance
AEs were analysed for all randomized patients (n=37).
An overview of all 58 AEs reported by 30 patients
(81.1%) is shown in Table 2. In group A (n=19), 10 grade
1, 18 grade 2, and 6 grade 3 AEs were reported by 16 pa-
tients (84.2%), whereas in group B (n=18), 9 grade 1, and
15 grade 2 AEs were reported by 14 patients (77.8%)
(Fisher’s exact, p=0.114). Five patients (26.3%) disconti-
nued intervention in group A, due to complaints of ab-
dominal pain and diarrhea (n=1), diarrhea (n=1), mood
alteration/depression (n=1), fatigue and anal/perianal
pain (n=1), and skin rash (n=1). Four patients (22.2%)
discontinued intervention in group B, due to complaints
of skin rash (n=1), chest pain, palpitations, and dyspnea
(n=1), dyspnea (n=1), and dyspepsia (n=1) (Fisher’s exact,
p=1.000). Two patients in group A reported insomnia and
Table 1 Base-line characteristics of patients with FAP
Overall
population
Group A: Group B: p value
Celecoxib&UDCA Celecoxib&Placebo
Number of patients 37 19 18
Age at study entry, median/range (yr) 42/22–67 42/22–67 41/27–64 0.9641
Sex (n, %) 0.6182
Male 18 (48.6) 10 (52.6) 8 (44.4)
Female 19 (51.4) 9 (47.4) 10 (55.6)
Participants per centre (n, %) 0.9323
RUNMC 18 (48.6) 10 (52.6) 8 (44.4)
AMC 10 (27.0) 4 (21.1) 6 (33.3)
EMC 4 (10.8) 2 (10.5) 2 (11.1)
UMCG 3 (8.1) 2 (10.5) 1 (5.6)
LUMC 2 (5.4) 1 (5.3) 1 (5.6)
Body Mass Index, median/range (kg/m2) 25.6/18.8–34.5 26.0/19.2–34.5 25.6/18.8–33.1 0.4081
Diagnosis FAP 0.6603
Clinical only 6 (16.2) 4 (21.2) 2 (11.1)
APC gene mutation 31 (83.8) 15 (78.9) 16 (88.9)
Age at primary CR surgery, median/range (yr) 21/7–60 22/7–60 18.5/11–48 0.2981
Time since primary CR surgery, median/range (yr) 18/1–38 17/1–33 20.5/8–38 0.1781
Type of primary CR surgery 0.7383
IRA 18 (48.6)* 10 (52.6)* 8 (44.4)
IPAA 14 (37.8) 6 (31.6) 8 (44.4)
Ileostomy 5 (13.5) 3 (15.8) 2 (11.1)
Secondary CR surgery (n, %) 11 (29.7) 5 (26.3) 6 (33.3) 0.6412
Spigelman stage at last surveillance before entry 0.9852
II 19 (51.4)** 10 (52.6) 9 (50)**
III 17 (45.9)** 9 (47.4) 8 (44.4)**
* Including one patient who underwent ileosigmoid anastomosis; ** In 1 case exact data on last previous surveillance duodenoscopy was missing; 1 The P value
was calculated using the Mann–Whitney U test; 2 The P value was calculated using the chi-square test; 3 The P value was calculated using the Fisher’s exact test.
FAP familial adenomatous polyposis, APC adenomatous polyposis coli, CR colorectal, IRA ileorectal anastomosism, IPAA ileal pouch-anal anastomosis; Ileostomy:
proctocolectomy with ileostomy, UDCA ursodeoxycholic acid, AMC Academic Medical Centre Amsterdam, EMC Erasmus Medical Centre Rotterdam, LUMC Leiden
University Medical Centre, RUNMC Radboud University Nijmegen Medical Centre, UMCG University Medical Centre Groningen.
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edema of the lower limbs respectively, which resolved
after reducing the celecoxib dose to halve the standard
trial dose. Both patients completed the intervention period
and were included in the analyses.
Compliance was evaluated in all patients that completed
the 6 months intervention period (n=28). In group A, the
median compliance for celecoxib and UDCA was 98.4%
(range: 82.4-100%) and 96.8% (range: 42.2-100%), respect-
ively. In group B, the median compliance for celecoxib
and placebo was 99.4% (range: 79.1-100%) and 97.0%
(range: 80.3-100%), respectively.
Discussion
This randomized controlled trial confirms that celecoxib
mono-treatment reduces duodenal polyp density in pa-
tients with FAP, whereas it demonstrates that celecoxib
and UDCA co-treatment has no beneficial effect. In con-
trast to our hypothesis of an expected additional effect
of the combination, our results imply that the clinical
improvement observed in patients treated with celecoxib
alone is counteracted by co-treatment with UDCA. We
found no changes in cell proliferation, apoptosis or
COX-2 expression in normal duodenal mucosa of pa-
tients with FAP, that could explain the observed effects.
The clinical improvement of duodenal polyp density
after treatment with celecoxib alone, confirms results
from a previous trial with similar design [19]. COX-2
overexpression was found in oesophageal [34], gastric
[35], colorectal [36], as well as small intestinal cancer
[37]. Multiple lines of evidence, including results from
in vitro, animal, and clinical studies, indicated that inhib-
ition of the increased COX-2 expression, at least in part
accounts for the anti-proliferative activity of celecoxib
[38]. In addition, COX-2 independent pathways were
suggested to be involved in the anti-proliferative effect
of celecoxib [38,39]. To our surprise, we found a high
COX-2 expression by immunohistochemical analyses,
but detected no COX-2 mRNA expression in normal
appearing duodenal mucosa of patients with FAP, neither
pre- nor post-intervention. Consequently, controversy
exists between assessment of COX-2 by immunohisto-
chemistry or qPCR assay. We assume that results on
COX-2 in immunohistochemistry could be based on
aspecific protein staining by the COX-2 antibody. As-
sessment of duodenal COX-2 mRNA levels by using
Quantigene Plex Assay, confirmed our findings with the
qPCR assay: COX-2 mRNA expression is extremely low
or even absent in normal duodenal mucosa of patients
with FAP (van Heumen et al., manuscript in prepar-
ation). Our results are in agreement with a previous re-
port of undetectable COX-2 mRNA levels in human
small intestinal mucosa by using qPCR analysis [37].
After prophylactic colectomy, duodenal bile compos-
ition changes and largely consists of cholic acid (CA)
and chenodeoxycholic acid (CDCA) [40]. In in vitro
models of human colon cancer cells, UDCA significantly
Figure 2 Box-Whisker plots of intention-to-treat and per-protocol analysis. Intention-to-treat analysis of mean score of change in duodenal
polyp density comparing duodenoscopic recordings pre- and post-intervention with either celecoxib & UDCA (group A) or celecoxib & placebo
(group B): clinical deterioration in group A (n=17, Wilcoxon Signed Rank, p=0.014), clinical improvement in group B (n=15, Wilcoxon Signed Rank,
p=0.029); difference in mean score between groups statistically significant (Mann–Whitney U, p=0.011). Per-protocol analysis: clinical deterioration
in group A (n=12, Wilcoxon Signed Rank, p=0.271), clinical improvement in group B (n=11, Wilcoxon Signed Rank, p=0.004); difference in mean
score between groups statistically significant (Mann–Whitney U, p<0.001). UDCA = ursodeoxycholic acid.
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reduced cytotoxicity of secondary bile acids [22]. By
UDCA supplementation in patients with FAP, up to 50%
enrichment of duodenal bile with UDCA was reached,
with a large reduction in concentration of the cytotoxic
CDCA [41]. Based on these findings, an inhibition of cell
proliferation was expected after UDCA supplementation.
Although we combined celecoxib and high dose UDCA
(~20-30 mg/kg daily), these in vitro effects could not be
reproduced in vivo in our trial. Moreover, our hypothesis
was in part based on clinical studies in patients with UC
Table 2 Adverse events in patients with FAP treated with either celecoxib & ursodeoxycholic acid or celecoxib & placebo
Treatment groups
CTCAE Category Name adverse event Group A Group B
n = 19 n = 18
Auditory/Ear Otitis, middle ear 1 (0/1/0) 0
Blood/Bone marrow Anemia - hemoglobin 1 (1/0/0) 0
Leukopenia 1 (0/1/0) 0
Cardiac arrhythmia Palpitations 0 2 (2/0/0)
Constitutional symptoms Fatique 2 (0/1/1) 1 (0/1/0)
Insomnia 1 (0/0/1) 0
Dermatology/Skin Hair loss - scalp 1 (1/0/0) 0
Rash 1 (0/1/0) 1 (0/1/0)
Gastrointestinal Constipation 2 (2/0/0) 2 (2/0/0)
Diarrhea 2 (1/1/0) 2 (2/0/0)
Heartburn/dyspepsia/nausea 4 (1/3/0) 2 (1/1/0)
Ulcera - oral 0 1 (1/0/0)
Ulcera - ileum/colon/rectum 1 (1/0/0) 0
Hepatobiliary/Pancreas Pancreas irritation* 0 1 (0/1/0)
Infection Infection - gastroenteritis 1 (0/1/0) 2 (0/2/0)
Infection - dental-tooth 1 (0/1/0) 1 (0/1/0)
Infection - skin 1 (0/1/0) 1 (0/1/0)
Lymphatics Edema - lower limbs 2 (1/1/0) 0
Metabolic/Laboratory Elevated AST, GGT 1 (1/0/0) 1 (1/0/0)
Hypokalemia 1 (0/0/1) 0
Neurology Dizzyness 1 (1/0/0) 0
Mood alteration - depression 1 (0/0/1) 0
Neuropathy - carpal tunnel syndrome 1 (0/1/0) 0
Pain Abdominal 1 (0/0/1) 0
Anal/perianal 4 (0/4/0) 1 (0/1/0)
Joint 0 1 (0/1/0)
Chest/thorax 0 1 (0/1/0)
Pulmonary/Upper respiratory Dyspnea 0 2 (0/2/0)
Nasal cavity/paranasal sinus reaction 0 2 (0/2/0)
Renal/Genitourinary Lower urinary tract symptoms - prostatism 1 (0/1/0) 0
Secondary malignancy Secondary malignancy - basalioma - nose 1 (0/0/1) 0
Total n of reported AE 34 (10/18/6)** 24 (9/15/0)**
Patients reporting ≥1 AE (n, %) 16 (84.2%) 14 (77.8%)
Number of specific adverse event reported during 6 month intervention in patients with FAP with either celecoxib & ursodeoxycholic acid (Group A) or celecoxib
& placebo (Group B), is depicted as grade 1, 2, or 3, as defined by the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Grade 4 and 5
adverse events did not occur. * Adverse event related to pre-intervention duodenoscopy; no other adverse events related to duodenoscopy were reported;
** Distribution of number of adverse events grade 1, 2, or 3, was not significantly different between treatment groups (Fisher’s exact, p=0.114). CTCAE Common
Terminology Criteria for Adverse Events, FAP familial adenomatous polyposis, AST aspartate aminotransferase, GGT gamma-glutamyl transpeptidase, AE
Adverse Event.
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and PSC showing chemopreventive effects of UDCA on
development of colorectal neoplasms [25,26]. Recently
however, treatment of patients with UC and PSC with
high dose UDCA (28-30 mg/kg daily) was found to be
associated with an increased risk of colorectal neoplasms
[42]. This could be an explanation for the disappointing
effect we obtained by the combination treatment of
celecoxib and high dose UDCA. In contrast, a recent
meta-analysis revealed that long-term low dose UDCA
treatment (8-15mg/kg daily) reduces the risk of ad-
vanced colorectal neoplasms in patients with UC and
PSC [43]. Extrapolating these results, long-term low
dose UDCA treatment could be expected to be effective
in patients with advanced duodenal adenomatosis. How-
ever, in a clinical trial in patients with FAP, no effects of
low dose UDCA (10 mg/kg daily) after 24 months as
mono-treatment were found on Spigelman scores [44].
Future studies that focus on the intracellular mechanisms
of action may elucidate the ambivalent effect of UDCA as
chemopreventive drug in (pre-) clinical studies.
The present study has several strenghts. First, it is the
first randomized clinical trial to investigate a combin-
ation of two potential chemopreventive drugs for duo-
denal adenomatosis in patients with FAP. Second, the
study population consists of an unique sample of pa-
tients with FAP from 5 out of the 8 Dutch University
Medical Centres. Third, bias due to interobserver vari-
ability was minimized, as primary outcome was based on
scores of polyp density by 5 gastroenterologists, who in-
dependently compared pre- and post-intervention videos
shown in random order, while blinded to treatment allo-
cation. The following limitations are noted. First, our
study lacks a ‘true placebo’ group. Hence, we were not
able to confirm the spontaneous reduction in duodenal
polyps in the placebo group, that was previously de-
scribed [19,44]. Second, changes in duodenal polyp
density are assessed qualitatively. In previous chemopre-
ventive studies on colorectal adenomatosis, changes in
polyp density were assessed by exact counting of polyp
number and measuring polyp diameter [12,45]. This
method is not suitable for assessment of the plaque-like
duodenal polyps, which are partially obscured due to
folding over the mucosal folds. Moreover, the curved
anatomy of the duodenum introduces an optic bias in
the two dimensional images obtained during endoscopy,
which further hampers reliable quantification. In clinical
practice, the Spigelman scoring system is an established
tool to assess duodenal adenomatosis and is commonly
used to plan follow up or treatment [4,46]. In clinical
science however, the Spigelman score seems insuffi-
ciently distinctive to detect subtle changes in polyp
density, and it does not account for peri-ampullary
adenomatosis specifically [47]. The applied method of
assessment in our study, which does include visual
assessment of the peri-ampullary region by side-viewing
duodenoscopy, permits adequate comparison with previ-
ous studies in the field [12,19,45]. Third, although we
were able to detect a significant difference in change in
duodenal polyp density between the two treatment
groups, sample size is fairly small. As the participants
already were under regular endoscopic surveillance and
a chemopreventive option to their benefit was the aim of
our study, we expected a high willingness to participate
in the trial. However, of all eligible patients with FAP
under regular surveillance in any of the five participating
centres, 31% declined informed consent. Reports of
cardiotoxicity of celecoxib [13,14,20] could have with-
held patients with FAP to participate. In addition, be-
cause of these reports, we applied strict exclusion
criteria, leaving out another 24% of patients. We seem-
ingly underestimated the required dedication to partici-
pate in the strenuous study protocol, which included a
relatively short follow-up interval of 6 months, as com-
pared to regular surveillance intervals of 2–3 years for
patients with Spigelman stage II and 1–2 years for pa-
tients with Spigelman stage III [46]. Chemopreventive
therapies should be well tolerated and have a low tox-
icity. During intervention period, up to 81% of patients
reported at least one adverse event, and 24% of patients
discontinued intervention due to adverse events. Al-
together, it seems unrealistic to expect that the regimens
under investigation in the present study, would be suit-
able as a life-time chemopreventive treatment.
In conclusion, high dose UDCA co-treatment completely
counteracts the positive effect of celecoxib, namely the
reduction of duodenal polyp density in patients with FAP.
It still needs investigation whether low dose UDCA co-
treatment does have a beneficial effects in this respect. The
benefit of long term use of celecoxib for duodenal cancer
prevention in patients with FAP needs to be weighed
against the potential risk of (cardiovascular) adverse events.
The search for effective chemopreventive strategies is on-
going and drugs of interest for patients with FAP include
sulindac and difluoromethylornithine [48], curcumin and
quercetin [49], and eicosapentaenoic acid [45]. Future re-
search has to result in suitable chemopreventive treatment
regimes to avoid radical duodenectomy or duodenal cancer.
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